ApoE genotype accounts for the vast majority of AD risk and AD pathology

Neurobiology of Aging

Volumn 25, Issue 5, 2004, Pages 641-650

  Raber, Jacob ^a   Huang, Yadong ^b   Ashford, J Wesson ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

AD pathology; AD risk; ApoE genotype

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; LIPID; SYNAPTOPHYSIN; TAU PROTEIN; THROMBIN;

AGE; AGING; ALLELE; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; BEHAVIOR DISORDER; BIOACCUMULATION; BRAIN; CARBOXY TERMINAL SEQUENCE; CELL INCLUSION; COGNITION; DISEASE COURSE; EPIDEMIOLOGICAL DATA; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CODE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; LIPID METABOLISM; MEMORY; METABOLIC REGULATION; NERVE CELL; NERVE CELL PLASTICITY; NERVE ENDING; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RODENT; SENILE PLAQUE; TRANSGENIC MOUSE; UNITED STATES;

EID: 2542502430     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2003.12.023     Document Type: Article

References (64)

1. Arendt T. Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization. Neuroscience. 102:2001;723-765
2. Ashford JW, Mattson M, Kumar V. Neurobiological systems disrupted. In: Kumar V, Eisdorfer C, editors. Advances in the diagnosis and treatment of Alzheimer's disease. New York: Springer Publishing Company; 1998.
3. Ashford J.W., Mortimer J.A. Non-familial Alzheimer's disease is mainly due to genetic factors. J. Alzheimer's Dis. 4:2002;169-177
4. Bales K.R., Verina T., Dodel R.C., Du Y., Altstiel L., Bender M., et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17:1997;263-264
5. V717F transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 96:1999;15233-15238
6. Buttini M., Shockley K., Huang Y., Jones B., Masliah E., Mallory M., et al. Modulation of Alzheimer-like synaptic and choninergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid β peptides but not on plaque formation. J. Neurosci. 22:2002;10539-10548
7. Cho H.S., Hyman B.T., Greenberg S.M., Rebeck G.W. Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Ab aggregation. J. Neuropathol. Exp. Neurol. 60:2001;342-349
8. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923
9. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.J., Roses A.D., et al. The apolipoprotein E E4 allele and sex-specific risk of Alzheimer's disease [letter comment]. JAMA. 273:1995;373-374
10. Czech C., Horstl H., Hentschel F., Monning U., Besthorn C., Geigerkabish C., et al. Apolipoprotein E-4 gene dose in clinically diagnosed Alzheimer's disease-prevalence. Eur. Arch. Psychiat. Clin. Neurosci. 243:1994;291-292
11. Evans D.A., Beckett L.A., Field T.S., Feng L., Albert M.S., Bennett D.A., et al. Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons. JAMA. 12(277):1997;822-824
12. Fagan A.M., Watson M., Parsadanian M., Bales K.R., Paul S.M., Holtzman D.M. Human and murine apoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9:2002;305-318
13. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 278:1997;1349-1356
14. Frisoni G.B., Louhija J., Geroldi C., Trabucchi M. Longevity and the epsilon2 allele of apolipoprotein E: the Finnish Centenarians Study. J. Gerontol. A Biol. Sci. Med Sci. 56:2001;M75-M78
15. Fullerton S.M., Clark A.G., Weiss K.M., Nickerson D.A., Taylor S.L., Stengard J.H., et al. Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am J. Hum. Genet. 67:2000;881-900
16. Gavrilov L.A., Gavrilova N.S. The reliability theory of aging and longevity. J. Theor. Biol. 213:2001;527-545
17. Ghebremedhin E., Schultz C., Braak E., Braak H. High frequency of apolipoprotein E epsilon4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes. Exp. Neurol. 153:1998;152-155
18. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:2002;353-356
19. Harris F.M., Brecht W.J., Xu Q., Tesseur I., Kekonius L., Wyss-Coray T., et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci USA. 100:2003;10966-10971
20. Hendrie H.C., Ogunniyi A., Hall K.S., Bayewu O., Unverzagt F.W., Gurejo O., et al. Incidence of dementia and Alzheimer's disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA. 285:2001;739-747
21. Hirsch H.R. Can an improved environment cause maximum lifespan to decrease? Comments on lifespan criteria and longitudinal Gompertzian analysis. Exp. Gerontol. 29:1994;119-137
22. Hirsch H.R. Do intersections of mortality-rate and survival functions have significance? Exp. Gerontol. 30:1995;147-167
23. Hirsch H.R. Intersections of mortality-rate and survival functions: model-independent considerations. Exp Gerontol. 32:1997;287-296
24. Holtzman D.M., Bales K.R., Tenkova T., Fagan A.M., Parsadanian M., Sartorius L.J., et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 97:2000;2892-2897
25. Huang Y., Liu X.Q., Wyss-Coray T., Brecht W.J., Sanan D.A., Mahley R.W. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc. Natl. Acad. Sci. USA. 98:2001;8838-8843
26. Huang Y, Weisgraber KH, Mucke L, Mahley RW. Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease. J Mol Neurosci 2004;32:187-202.
27. V717F transgenic mice. Acta Neuropathol. 100:2000;451-458
28. Jorm A.F., Jolley D. The incidence of dementia: a meta-analysis. Neurology. 51:1998;728-733
29. LaDu M.J., Falduto M.T., Manelli A.M., Reardon C.A., Getz G.S., Frail D.E. Isoform-specific binding of apolipoprotein E to b-amyloid. J. Biol. Chem. 269:1994;23403-23406
30. LaDu M.J., Pederson T.M., Frail D.E., Reardon C.A., Getz G.S., Falduto M.T. Purification of apolipoprotein E attenuates isoform-specific binding to β-amyloid. J. Biol. Chem. 270:1995;9039-9042
31. Lanz T.A., Carter D.B., Merchant K.M. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol Dis. Aug. 13:2003;246-253
32. Levi O., Jongen-Relo A.L., Feldon J., Roses A.D., Michaelson D.M. ApoE4 impairs hippocampal plasticity isoform-specifically and blocks the environmental stimulation of synaptogenesis and memory. Neurobiol. Dis. 13:2003;273-282
33. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer b-protein into filaments. Nature. 372:1994;92-94
34. Mahley R, Huang Y, Apolipoprotein E. Structure and function in lipid metabolism and neurobiology. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, Nestler EJ, editors. The molecular and genetic basis of neurologic and psychiatric disease, third ed. Philadelphia: Butterworth Heinemann; 2003. p. 565-73.
35. Mayeux R., Saunders A.M., Shea S., Mirra S., Evans D., Roses A.D., et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N. Engl. J. Med. 338:1998;506-511
36. Marz W., Scharnagl H., Kirca M., Bohl J., Gross W., Ohm T.G. Apolipoprotein E polymorphism is associated with both senile plaque load and Alzheimer-type neurofibrillary tangle formation. Ann N Y Acad. Sci. 777:1996;276-280
37. Mesulam M.M. A plasticity-based theory of the pathogenenesis of Alzeimer's disease. Ann. N. Y. Acad. Sci. 924:2000;42-52
38. Miech R.A., Breitner J.C., Zandi P.P., Khachaturian A.S., Anthony J.C., Mayer L. Incidence of AD may decline in the early 90s for men, later for women: the Cache County study. Neurology. 58:2002;209-218
39. Moir R.D., Atwood C.S., Romano D.M., Laurans M.H., Huang X., Bush A.I., et al. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of Ab using physiological concentrations. Biochemistry. 38:1999;4595-4603
40. Nagy Z.S., Esiri M.M., Jobst K.A., Johnston C., Lichtfiel S., Sim E., et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience. 69:1995;757-761
41. Namba Y., Tomonoga M., Kawasaki E., Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541:1991;163-166
42. Raber J., Wong D., Buttini M., Orth M., Bellosta S., Pitas R.E., et al. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc. Natl. Acad. Sci. USA. 95:1998;10914-10919
43. Raber J., Wong D., Yu G.Q., Buttini M., Mahley R.W., Pitas R.E., et al. Apolipoprotein E and cognitive performance. Nature. 404:2000;352-354
44. Raber J., Bonger G., LeFevour A., Buttini M., Mucke L. Androgens protect against apolipoprotein E4-indiced cognitive deficits. J. Neurosci. 22:2002;5204-5209
45. Reed T., Carmelli D., Swan G.E., Breitner J.C., Welsh K.A., Jarvik G.P., et al. Lower cognitive performance in normal older adult male twins carrying the apolipoprotein E epsilon 4 allele. Arch. Neurol. 51:1994;1189-1192
46. Roses A.D. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. Ann Neurol. 38:1995;6-14
47. Roses A.D. Apolipoprotein E and Alzheimer's disease. A rapidly expanding field with medical and epidemiological consequences. Ann. N Y Acad. Sci. 802:1996;50-57
48. Sanan D.A., Weisgraber K.H., Russell S.J., Mahley R.W., Huang D., Saunders A., et al. Apolipoprotein E associates with b amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J. Clin. Invest. 94:1994;860-869
49. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 43:1993;1467-1472
50. Schmechel D.E., Saunders A.M., Strittmatter W.J., Crain B.J., Hulette C.M., Joo S.H., et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein-E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90:1993;9649-9653
51. Selkoe D.J. Clearing the brain's amyloid cobwebs. Neuron. 32:2001;177-180
52. Silverman J.M., Smith C.J., Marin D.B., Mohs R.C., Propper C.B. Familial patterns of risk in very late-onset Alzheimer disease. Arch. Gen. Psychiatry. 60:2003;190-197
53. Small G.W., Ercoli L.M., Silverman D.H., Huang S.C., Komo S., Bookheimer S.Y., et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 97:2000;6037-6042
54. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L-M., Salvesen G.S., Pericak-Vance M. Binding of human apolipoprotein E to synthetic amyloid (peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90:1993;8098-8102
55. Tesseur I., Van Dorpe J., Spittaels K., Van den Haute C., Moechars D., Van Leuven F. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J. Pathol. 156:2000;951-964
56. Teter B., Ashford J.W. Neuroplasticity in Alzheimer's disease. J. Neurosci. Res. 70:2002;402-437
57. Tolar M., Marques M.A., Harmony J.A.K., Crutcher K.A. Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J. Neurosci. 17:1997;5678-5686
58. Tolar M., Keller J.N., Chan S., Mattson M.P., Marques M.A., Crutcher K.A. Truncated apolipoprotein E (apoE) causes increased intracellular calcium and may mediate apoE neurotoxicity. J. Neurosci. 19:1999;7100-7110
59. Tsuboi Y., Josephs K.A., Cookson N., Dickson D.W. APOE E4 is a determininant for Alzheimer type pathology in progressive supranuclear palsy. Neurology. 60:2003;240-245
60. Umberger GHH, Andersen AH, Kryscio RJ, Blonder LX, Schmitt FA, Wekstein DA, et al. Longitudinal functional alterations in asymptotic women at risk for Alzheimer's disease. Society for Neuroscience Abstract; 2003. p. 240.7.
61. Warzok R.W., Kessler C., Apel G., Schwarz A., Egensperger R., Schreiber D., et al. Apolipoprotein E4 promotes incipient Alzheimer pathology in the elderly. Alzheimer Dis. Assoc. Disord. 12:1998;33-39
62. Wisniewski T., Castaño E.M., Golabek A., Vogel T., Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145:1994;1030-1035
63. Wisniewski T., Lalowski M., Golabek A., Vogel T., Frangione B. Is Alzheimer's disease an apolipoprotein E amyloidosis? Lancet. 345:1995;956-958
64. Yaffe K., Cauley J., Sands L., Browner W. Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch. Neurol. 54:1997;1110-1114